While 340B ESP provides an avenue to assist Covered Entities in regaining access to 340B medications to continue supporting underserved patients, the complexity and timeliness issues inherent in 340B ESP have created many new challenges.
Managing compliance while also optimizing program performance and ensuring continued revenue success are essential to a robust 340B Program, even more as a result of the hits that CEs have taken as a result of manufacturers refusal to provide 340B prices for contract pharmacy over the past two years.
Visante’s 340B consulting practice has successfully supported dozens of clients with various aspects of 340B ESP submission and revenue recovery and has developed a unique approach to best support our clients’ needs. Kristin Fox-Smith, Managing Director, and Angela De Ianni, Senior director, will present 5 practical tips to navigate 340B ESP and optimize your program performance:
Topics to cover:
Managing Director, 340B ACE Visante
Managing Director, 340B ACE Visante
Kristin Fox-Smith (MPA) brings more than 20 years’ experience to Visante clients, specializing in 340B Program audits and specialty pharmacy assessments and implementations. In addition, she has expertise in coding and billing issues for oncology, solid organ transplant and bone marrow services, inpatient and outpatient mental health, as well as for long-term care and HIV/AIDS.
Kristin manages the oversight and strategic direction of 340B engagements for Visante. Along with her consultant team, she has conducted audits of more than 75 covered entities representing almost every type of 340B covered entity. Together, they have audited more than 4000 contract pharmacy locations including Walgreens, Walmart, Rite Aid, CVS, grocery store chains, and independent pharmacies. She has overseen 340B Program assessments that include the analysis and creation of contract pharmacy networks as well as support for covered entities new to the 340B Program. For these she provides education, policy and procedure creation, along with setting up best practices for a successful 340B Program with compliance at its core. She also has experience with all 340B split billing vendors and has assisted covered entities with the analysis, implementation, and maintenance of these platforms.
Senior Director, Visante
Senior Director, Visante
Angela (RPh, MBA) is equipped with a broad range of experiences in hospitals, clinics, and retail pharmacies. Her skills in finance, operations, supply chain, specialty pharmacy, contracting, and the 340B drug discount program make her well versed in health-system pharmacy.
Before joining Visante, Angela was with Advocate Aurora Health Care, where she started as a Director of Inpatient Pharmacy until she was promoted to Vice President of Pharmacy Supply Chain. As a Director, Angela proved to be highly productive at budgeting and analyzing performance data to determine areas for improvement. In addition, she put quality patient care at the forefront of her strategies by collaborating with clinical and non-clinical leaders. As Vice President, Angela led the 340B Drug Discount Program, inventory management, critical drug shortages, and vendor relations. She also managed the purchasing and contracting of pharmaceutical products for hospitals, clinics, and retail pharmacies.
Visante is a specialized consulting firm focused on helping health systems accelerate strong financial and operational performance through pharmacy. Our team of professionals brings deep, contemporary expertise and innovation to optimizing all aspects of a fully integrated health system pharmacy program, driving significant value quickly. By providing customized solutions to fit the needs of our clients, we deliver sustained financial results through revenue growth, cost savings, assured compliance and optimal business performance. Learn more at visanteinc.com.
Your registration may be transferred to a member of your organization up to 24 hours prior to the first day of the event. All cancellations must be received in writing no later than 30 calendar days prior to the first day of the event to receive a refund less the $195.00 administrative charge. No refunds will be made after this date. However, the registration fee less the $195.00 administrative charge can be credited toward another comparable event (registration must be received within 6 months of the event from which you cancel). In case of conference cancellation, The Healthcare Innovation Company’s liability is limited to refund of conference registration fee only. Programs are subject to change, and we reserve the right to alter all programs without prior notice.